Search This Blog

Wednesday, March 22, 2023

Novartis: Sandoz receives US FDA approval for Humira biosimilar high-concentration

 

  • Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®*

  • With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation

  • Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)